University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Michael D. Prados, MD

Michael D. Prados, MD

Professor, Department of Neurological Surgery, and Director of Translational Research in Neuro-Oncology, UCSF
Charles B. Wilson, MD, Endowed Chair in Neurological Surgery, UCSF

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

Michael Prados began his career in Neuro-Oncology as a Fellow at the University of California San Francisco in 1985. Following a two year training program, he was recruited to the Faculty in 1988 and has remained at UCSF since that time, and holds the Charles B Wilson Chair in Neurosurgery. His career interests center around patient care, and clinical and translational research. He became the Project Leader of the North America Brain Tumor Consortium (NABTC), an NCI-CTEP supported multi-institutional early phase clinical trials consortium, and led that group for 15 years. When the NABTC merged with the NABTT (and became the Adult Brain Tumor Consortium) he was named co-Project Leader until stepping down in early 2014. In 2009, he was awarded the Project Leadership of what is called the Ivy Foundation Early Phase Clinical Trials Consortium, a group of now 7 major academic centers who conduct clinical and translation research in adults with brain cancer. This group is now led by Nicholas Butowski, MD at UCSF.

He was the Institutional site Principal Investigator for the Pediatric Brain Tumor Consortium (PBTC) for over 10 years, ending that role in 2012. Shortly thereafter he formed the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of now 15 major academic centers across the United States, conducing early phase, precision-focused, clinical trials in young children and adolescents. Dr. Prados retired from UCSF in October 2015, and the PNOC is now led by Sabine Mueller, MD, PhD.

UCSF requested that Dr. Prados return on a part-time basis in January 2016 as Professor Emeritus, to devote his efforts towards pediatric Neuro-Oncology clinical and translational research. Towards that end, he is the co-Project Leader of a pediatric brain tumor SPORE project at UCSF, and is co-Project Leader of the PNOC. His academic appointments are within Neurosurgery, retaining the Charles B. Wilson endowed chair, and the Department of Pediatrics.

His major interests are early phase clinical trials research, and the translational studies that precede and inform those trials in both adults and children. He has published over 300 articles since 1985, has been NIH/NCI funded continuously since 1994 and is part of the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.

Education

Mississippi State University, Starkville, 1966-1969, Biology
University of New Orleans, BS, 1969-1970, Biology
LSU School of Medicine, MD, 1970-1974, Medicine
LSU Charity Hospital, New Orleans, LA, Internship, 1974-1975, Medicine
LSU Earl K Long Hospital, Baton Rouge, LA, Residency, 1975-1977, Internal Medicine


Professional Experience

  • 1977-1978
    Instructor, Department of Internal Medicine, LSU School of Medicine, New Orleans, LA
  • 1979-1982
    Assistant Professor, Department of Medicine, LSU School of Medicine, Earl K Long Hospital, Baton Rouge, LA
  • 1980-1982
    Clinical Director, Medical Oncology, Dept. of Medicine, LSU School of Medicine, Earl K Long Hospital, Baton Rouge, LA
  • 1983-1984
    Pulmonary Fellowship (12 months), Tulane University School of Medicine, New Orleans, LA
  • 1984-1985
    Asst. Clinical Director, Dept. of Pulmonary Medicine, Touro Infirmary, New Orleans, LA
  • 1985-1987
    Clinical Instructor, Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, University of California, San Francisco, CA
  • 1988-1991
    Asst. Clinical Prof., Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, School of Medicine, University of California, San Francisco, CA
  • 1988-1989
    Acting Director, Neuro-Oncology Program, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco
  • 1989-2005
    Director, Neuro-Oncology Program, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco
  • 1991-1995
    Assoc. Clinical Professor, Chief, Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, School of Medicine, University of California, San Francisco, CA
  • 1995-present
    Professor in Residence, Dept. of Neurological Surgery, University of California, San Francisco
  • 2001-present
    Charles B. Wilson Professor of Neurological Surgery, University of California, San Francisco
  • 2005 - present
    Director of the Translational Research Program in Neuro-Oncology, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco

Selected Publications

  1. McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ. Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM. Mol Cancer Ther. 2019 Jul 03.
    View on PubMed
  2. Mueller S, Jain P, Liang WS, Kilburn L, Kline C, Gupta N, Panditharatna E, Magge SN, Zhang B, Zhu Y, Crawford JR, Banerjee A, Nazemi K, Packer RJ, Petritsch CK, Truffaux N, Roos A, Nasser S, Phillips JJ, Solomon D, Molinaro A, Waanders AJ, Byron SA, Berens ME, Kuhn J, Nazarian J, Prados M, Resnick AC. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. Int J Cancer. 2019 Mar 12.
    View on PubMed
  3. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 Mar 20; 37(9):741-750.
    View on PubMed
  4. Panditharatna E, Kilburn LB, Aboian MS, Kambhampati M, Gordish-Dressman H, Magge SN, Gupta N, Myseros JS, Hwang EI, Kline C, Crawford JR, Warren KE, Cha S, Liang WS, Berens ME, Packer RJ, Resnick AC, Prados M, Mueller S, Nazarian J. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clin Cancer Res. 2018 Dec 01; 24(23):5850-5859.
    View on PubMed
  5. Gupta N, Goumnerova LC, Manley P, Chi SN, Neuberg D, Puligandla M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Rubin JB, Gauvain K, Limbrick D, Leonard J, Geyer JR, Leary S, Browd S, Wang Z, Sood S, Bendel A, Nagib M, Gardner S, Karajannis MA, Harter D, Ayyanar K, Gump W, Bowers DC, Weprin B, MacDonald TJ, Aguilera D, Brahma B, Robison NJ, Kiehna E, Krieger M, Sandler E, Aldana P, Khatib Z, Ragheb J, Bhatia S, Mueller S, Banerjee A, Bredlau AL, Gururangan S, Fuchs H, Cohen KJ, Jallo G, Dorris K, Handler M, Comito M, Dias M, Nazemi K, Baird L, Murray J, Lindeman N, Hornick JL, Malkin H, Sinai C, Greenspan L, Wright KD, Prados M, Bandopadhayay P, Ligon KL, Kieran MW. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 Oct 09; 20(11):1547-1555.
    View on PubMed
  6. Young JS, Prados MD, Butowski N. Using genomics to guide treatment for glioblastoma. Pharmacogenomics. 2018 Oct; 19(15):1217-1229.
    View on PubMed
  7. Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 Sep 03; 20(10):1411-1418.
    View on PubMed
  8. Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol. 2018 Nov; 140(2):477-483.
    View on PubMed
  9. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 Aug 02; 20(9):1240-1250.
    View on PubMed
  10. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol. 2018 03 27; 20(4):546-556.
    View on PubMed
  11. Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258.
    View on PubMed
  12. Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):259-267.
    View on PubMed
  13. Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, Brandes AA, Reiss M, Goldman S, Fisher MJ, Pollack IF, Prados MD, Wen PY, Chang SM, Dufour C, Zurakowski D, Kortmann RD, Kieran MW. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro Oncol. 2018 01 10; 20(1):13-23.
    View on PubMed
  14. Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 Jan 15; 24(2):295-305.
    View on PubMed
  15. Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J Neurooncol. 2018 Jan; 136(1):79-86.
    View on PubMed
  16. Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 2017 Aug 01; 19(8):1135-1144.
    View on PubMed
  17. Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. 2017 Dec 01; 123(23):4631-4639.
    View on PubMed
  18. Ulasov IV, Foster H, Butters M, Yoon JG, Ozawa T, Nicolaides T, Figueroa X, Hothi P, Prados M, Butters J, Cobbs C. Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy. J Neurooncol. 2017 Jun; 133(2):257-264.
    View on PubMed
  19. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 03; 79(3):603-610.
    View on PubMed
  20. Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017 02 01; 19(2):242-251.
    View on PubMed

Go to UCSF Profiles, powered by CTSI